Suguru Ueno joinedJAFCO in 2025. He is a part of the Industry/Academia/Life Sciences Investment Group, focusing on investments in and support for R&D‑driven startups. He holds a PhD in Pharmaceutical Sciences from the University of Tokyo. From 2011, he worked at Daiichi Sankyo’s Antibody Pharmaceuticals Research Laboratories and at U3 Pharma in Germany, where he proposed antibody–drug conjugate themes and conducted non‑clinical research. As a global project leader in the Oncology Clinical Development Department, he planned and advanced development strategies, confirming clinical proof of concept. From 2019, he engaged in novel allogeneic cell therapy research at Daiichi Sankyo’s Cell Therapy Research Laboratories, and since 2023 he has been a visiting researcher in neurophysiology and chemistry at Stanford University, conducting basic research connecting biology and devices.